The latest biotech news

News and Trends 4 Oct 2016

One Step Closer to an HIV Cure That Can Eliminate the Latent Virus

HIV has completely disappeared from the blood of a patient in clinical trials. The new HIV treatment that can target the virus even in its dormant state by activating latent infected cells and could possibly become the first HIV cure available. These initial results show that the new therapy, developed in the UK, may be effective in curing HIV. One of 50 […]

October 4, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 4 Oct 2016

Top 10 European Biotech Entrepreneurs Under 30 in 2016

As a young entrepreneur myself, I’m always impressed by other young entrepreneurs with crazy and ambitious ideas. Here are the most inspiring innovators under 30 years in European Biotech this year! Disclaimers first! Yes, this ranking is obviously very subjective. Yes, I did look for women, but as a reflection of the gender imbalance in biotech […]

October 4, 2016 - 6 minutesmins - By Philip Hemme

News and Trends 3 Oct 2016

Idriss J. Aberkane: Biomimetics could lead to the next Renaissance?

How can the observation of nature help us solve scientific, economic and social challenges? The French entrepreneur, Idriss J. Aberkane, discusses biomimetics as the next intellectual revolution. Let’s start with an analogy: if the history of our planet Earth was compressed into 1 year, humans would appear in the last 15 minutes of it. Out […]

October 3, 2016 - 8 minutesmins - By Marie Godar

News and Trends 3 Oct 2016

Researchers Find New Weak Spots to Develop an HIV Cure

Last week we published a thorough review on current approaches for an HIV cure, which may be available as soon as 2020. Academia has come up with two additional strategies that could make a huge difference in the study of HIV. HIV affects 36.7 million people in the world and caused 1.1 million deaths last year. Plenty of resources […]

October 3, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 3 Oct 2016

Ask the Biotech Recruiter: The Top 10 Pitfalls in International Recruitments

Are you recruiting talent for the top levels of your company? Ask the biotech recruiter! It doesn’t matter if you’re a small-time biotech or a big-time pharma – it’s a tough process. Pact & Partners, a leading international headhunting firm, has your back with this advice on the most common mistakes and how to avoid […]

October 3, 2016 - 9 minutesmins - By External Contributor

News and Trends 1 Oct 2016

This Belgian Bioartist is deconstructing Chicken Evolution

Koen Vanmechelen is an artist that works in the intersection of art and research. His art focuses on exploring biocultural diversity… using chickens! Koen Vanmechelen‘s core artistic work is the Cosmopolitan Chicken Project (CCP), in which the artist cross-breeds chickens from all around the world. The aim: to create the ultimate chicken that will combine genes from […]

October 1, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

Screenshot 2016 09 29 at 4.53.52 PM e1475160985987

News and Trends 30 Sep 2016

Tailored Cancer Vaccines? NousCom is working on it!

We aren’t leaving Switzerland yet! We took a scenic train to Basel in order to meet nousCom, a very young biotech developing cancer vaccines. City: Basel, Switzerland Founded: 2015 Employees: unknown Financial Data: €12M raised in series A Mission: NousCom is a Biotech that develops next generation cancer vaccines with patient- and tumor-specific antigens. Their vaccines combine viruses […]

September 30, 2016 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 30 Sep 2016

Interview: GeNeuro’s CFO explains its Unique Multiple Sclerosis Treatment

GeNeuro is developing a unique treatment for multiple sclerosis. We interviewed Miguel Payro, the company’s CFO, who explained its advantageous position against big pharma. GeNeuro raised €33M in its Euronext IPO in April and is currently competing against giants like Novartis and Biogen. Despite 2016’s dubious honor as “the worst year for IPO in 20 years”, this Switzerland-based company has managed to go […]

September 30, 2016 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 29 Sep 2016

Boehringer buys a €210M ticket to Virus-based Immuno-Oncology

Boehringer Ingelheim has signed a deal with ViraTherapeutics, an Austrian start-up that focuses on the development of oncolytic virus therapies. If everything goes well, the big Pharma could acquire the Biotech start-up after completion of Phase I trials. Boehringer Ingelheim has its eye on ViraTherapeutics’ oncolytic virus platform. The young Biotech’s technology establishes a novel treatment approach that […]

September 29, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 29 Sep 2016

Interview: This Biotech Could Have the First HIV Cure on the Market

InnaVirVax is one of the most advanced companies in the race to develop an HIV cure. At the SACHS Conference in Basel, we had the opportunity to pick the brain of the CEO, Joël Crouzet, about his company’s progress. Last week, we reviewed progress in biotech towards an HIV cure, which could hit the market […]

September 29, 2016 - 1 minutemin - By Evelyn Warner

News and Trends 29 Sep 2016

Titans in Gene Therapy and TCRs make a Massive Deal

Medigene has licensed a few candidates from its TCR platform to one of the Boston ‘it’ biotechs in a deal totaling around €1B. By partnering with bluebird bio, Medigene is reestablishing itself as a leader in immuno-oncology. Founded over 20 years ago, Medigene has risen to the top of the European biotech scene with a […]

September 29, 2016 - 3 minutesmins - By Evelyn Warner

News and Trends 29 Sep 2016

Debunking the Immuno-Oncology Hype: is it as good as it sounds?

CAR-T therapies have gained plenty of attention lately by promising to end cancer with a one-off treatment. But all that glitters is not gold; experts remind us it is important to be critical about the immuno-oncology hype. Immuno-oncology has become all the rage lately, and the hype has led to some major investments, acquisitions, deals and partnerships. It seems […]

September 29, 2016 - 5 minutesmins - By Clara Rodríguez Fernández

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

One Step Closer to an HIV Cure That Can Eliminate the Latent Virus

Top 10 European Biotech Entrepreneurs Under 30 in 2016

Idriss J. Aberkane: Biomimetics could lead to the next Renaissance?

Researchers Find New Weak Spots to Develop an HIV Cure

Ask the Biotech Recruiter: The Top 10 Pitfalls in International Recruitments

This Belgian Bioartist is deconstructing Chicken Evolution

Tailored Cancer Vaccines? NousCom is working on it!

Interview: GeNeuro’s CFO explains its Unique Multiple Sclerosis Treatment

Boehringer buys a €210M ticket to Virus-based Immuno-Oncology

Interview: This Biotech Could Have the First HIV Cure on the Market

Titans in Gene Therapy and TCRs make a Massive Deal

Debunking the Immuno-Oncology Hype: is it as good as it sounds?

Subscribe to our newsletter to get the latest biotech news!